US20120015913A1 - Formulations of 14-EPI-Analogues of Vitamin D - Google Patents

Formulations of 14-EPI-Analogues of Vitamin D Download PDF

Info

Publication number
US20120015913A1
US20120015913A1 US12/836,974 US83697410A US2012015913A1 US 20120015913 A1 US20120015913 A1 US 20120015913A1 US 83697410 A US83697410 A US 83697410A US 2012015913 A1 US2012015913 A1 US 2012015913A1
Authority
US
United States
Prior art keywords
epi
vitamin
analogue
oral formulation
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/836,974
Inventor
Rémi Delansorne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybrigenics SA
Original Assignee
Hybrigenics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybrigenics SA filed Critical Hybrigenics SA
Priority to US12/836,974 priority Critical patent/US20120015913A1/en
Assigned to HYBRIGENICS SA reassignment HYBRIGENICS SA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DELANSORNE, REMI
Priority to SG2013002902A priority patent/SG187071A1/en
Priority to AU2011278352A priority patent/AU2011278352B2/en
Priority to NZ606678A priority patent/NZ606678A/en
Priority to JP2013519093A priority patent/JP5836372B2/en
Priority to UAA201301824A priority patent/UA110211C2/en
Priority to CA2805198A priority patent/CA2805198C/en
Priority to KR1020137003059A priority patent/KR101821440B1/en
Priority to PL11173836T priority patent/PL2407154T3/en
Priority to KR1020137003060A priority patent/KR101821441B1/en
Priority to US13/182,239 priority patent/US9314474B2/en
Priority to SI201130012T priority patent/SI2407154T1/en
Priority to CN201180043277.7A priority patent/CN103096877B/en
Priority to EP11173860A priority patent/EP2407155B1/en
Priority to PCT/EP2011/061973 priority patent/WO2012007512A1/en
Priority to US13/182,251 priority patent/US20120015915A1/en
Priority to BR112013000930A priority patent/BR112013000930A2/en
Priority to PCT/EP2011/061984 priority patent/WO2012007517A1/en
Priority to EP11173836A priority patent/EP2407154B1/en
Priority to RU2013106493/15A priority patent/RU2575792C2/en
Priority to PT111738365T priority patent/PT2407154E/en
Priority to SI201130021T priority patent/SI2407155T1/en
Priority to JP2013519097A priority patent/JP5836373B2/en
Priority to RU2013106492/15A priority patent/RU2575819C2/en
Priority to MX2013000539A priority patent/MX2013000539A/en
Priority to DK11173836.5T priority patent/DK2407154T3/en
Priority to CN2011800432762A priority patent/CN103096876A/en
Priority to AU2011278346A priority patent/AU2011278346B2/en
Priority to ES11173860T priority patent/ES2401715T3/en
Priority to ES11173836T priority patent/ES2398640T3/en
Priority to DK11173860.5T priority patent/DK2407155T3/en
Priority to PL11173860T priority patent/PL2407155T3/en
Priority to BR112013000941A priority patent/BR112013000941A2/en
Priority to NZ606679A priority patent/NZ606679A/en
Priority to CA2805203A priority patent/CA2805203A1/en
Priority to PT111738605T priority patent/PT2407155E/en
Priority to SG2013002910A priority patent/SG187072A1/en
Priority to PCT/EP2011/062127 priority patent/WO2012007570A2/en
Publication of US20120015913A1 publication Critical patent/US20120015913A1/en
Priority to IL224191A priority patent/IL224191A/en
Priority to IL224192A priority patent/IL224192A/en
Priority to HRP20130093AT priority patent/HRP20130093T1/en
Priority to HRP20130237AT priority patent/HRP20130237T1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones

Definitions

  • the present invention concerns improved formulations of 14-epi-analogues of vitamin D.
  • Vitamin D belongs to the group of fat-soluble vitamins, together with vitamins A, E and K.
  • the two main natural forms of vitamin D: vitamin D 2 (also named ergocalciferol) and vitamine D 3 (also named cholecalciferol) are soluble in lipids and insoluble in water, like all their chemical derivatives.
  • Vitamin D its metabolites and analogues have potent effects on calcium and phosphate metabolism and can therefore be used for prevention and therapy of vitamin D deficiency, such as rickets and other disorders of plasma and bone mineral homeostasis such as osteoporosis and osteomalacia.
  • vitamin D receptors and vitamin D activity have also been documented in numerous other tissues and cells, where they are also known to be involved in cell proliferation and differentiation.
  • Vitamin D also affects the immune system as vitamin D receptors are expressed in several white blood cells including monocytes, macrophages and T and B lymphocytes.
  • vitamin D compounds as active pharmaceutical ingredients show a large variety: ergocalciferol is available in solution in ethanol for oral administration or in arachis oil for injection since 1940; cholecalciferol is marketed as a solution in medium-chain triglycerides (MCT) both for oral and injectable administrations since 1964; in 1974, a droplet formulation of calcifediol (25-hydroxy-cholecalciferol) in solution in propylene glycol was introduced; in 1979, alfacalcidol (1-hydroxy-cholecalciferol) was approved for oral administration as soft gelatin capsules filled with solution in sesame oil; in 1982, calcitriol (1,25-dihydroxy-cholecalciferol) was launched in soft gelatin capsules filled with solution in MCT; in 1989, a new formulation of cholecalciferol was made available as drinking solution in a complex mixture of polyoxyethylenated glycerides, propylene glycol, glycerol,
  • vitamin D derivatives for various therapeutic applications such as disorders of the immune system, hormone secretion, cell differentiation or cell proliferation.
  • such compounds may be useful in the therapy of disorders characterized by increased cell proliferation, such as psoriasis and/or cancer.
  • 1,25(OH) 2 -vitamin D 3 the active metabolite of vitamin D 3 named calcitriol, is known to inhibit the proliferation of many cancer cells lines of various origins in vitro and to slow the progression of various tumor xenografts in vivo.
  • EP 0 707 566 B1 discloses a number of calcitriol analogues such as 14-epi-analogues.
  • 14-epi-analogues of calcitriol is inecalcitol of formula:
  • Inecalcitol is the international non-proprietary name for 19-nor-9,10-seco-146H-cholesta-5(Z),7(E)-dien-23-ino-1 ⁇ ,3 ⁇ ,25-triol-23-yne (C 26 H 40 O 3 ).
  • Inecalcitol is a synthetic derivative of calcitriol, the natural active metabolite of vitamin D 3 .
  • Eelen et al. Molecular Pharmacology 67, 1566-1573, 2005
  • Verlinden et al. Journal of Bone and Mineral Research , volume 16(4), 625-638, 2001
  • Inecalcitol is an original vitamin D analogue different from all other vitamin D derivatives by the cis conformation of the junction between the C and D rings of the molecule, rather than the trans configuration in the natural vitamin D compounds (Verlinden et al., 2000, Cancer Res., 60. 2673-2679).
  • This modification also called 14-epimerization, has been described for the first time by Maynard et al. (1994, J. Med. Chem., 37, 2387-2393) in the vitamin D series, and only very seldom applied to synthesize new 14-epi-vitamin D analogues (W0 2004 080922 and related patent documents; U.S. Pat. No.
  • Inecalcitol is the most advanced 14-epi vitamin D derivative in terms of clinical development: it has been tested both in healthy volunteers and in human patients by oral administration in the classical formulation as a solution in MCT in soft gelatin capsules, like elocalcitol, paricalcitol, doxercalciferol, calcitriol and the first formulation of cholecalciferol.
  • inecalcitol profile is its very low calcemic activity, especially in monkeys and human subjects, allowing the oral administration of very high doses.
  • the maximal tolerated (MDT) dose is 4 mg per day, much higher than the MTD of any other vitamin D analogue previously determined: 10 ⁇ g per day for seocalcitol, 45 ⁇ g once a week for calcitriol and 150 ⁇ g per day for elocalcitol.
  • inecalcitol as a representative of a unique physico-chemical class of 14-epi-derivatives of vitamin D, also differs for the range of dose at which it can be administrated. Both reasons may explain the unpredictable results obtained with high dose formulations of inecalcitol orally administrated to monkeys as test animals, more representative of human tolerance than rats.
  • the usual formulations of vitamin D derivatives may not be optimized for the 14-epi-analogues. It is thus desirable to provide improved formulations of 14-epi-analogues of vitamin D, in particular inecalcitol.
  • MCT Medium Chain Triglycerides
  • the formulations of the invention exhibit at least two-fold increase of the Cmax peak of the MCT formulation in mammals, such as in human and/or monkeys.
  • the formulations of the invention may also exhibit additionally or alternatively an improved overall bioavailability (AUC 0-24h ) over the Medium Chain Triglycerides formulation of said 14-epi-analogues of vitamin D.
  • AUC 0-24h an improved overall bioavailability
  • the formulations of the invention lead to a higher AUC 0-24h than the Medium Chain Triglycerides formulation of said 14-epi-analogues of vitamin D in mammals, such as in human and/or monkeys.
  • the present invention concerns an oral formulation of a 14-epi-analogue of vitamin D characterized by an improved absorption profile over the Medium Chain Triglycerides (MCT) formulation of said 14-epi-analogues of vitamin D.
  • MCT Medium Chain Triglycerides
  • the present invention also concerns an oral formulation of a 14-epi-analogue of vitamin D for use for improving the absorption of said 14-epi-analogue over the formulation in medium chain triglycerides.
  • the improved absorption profile is such that the oral formulations of the invention have a higher peak concentration (Cmax) and may additionally exhibit a higher overall absorption (AUC 0-24h ) than the corresponding formulation in MCT of said 14-epi-analogue of vitamin D.
  • 14-epi-analogue of vitamin D refers to analogues of vitamin D derivatives, such as ergocalciferol, cholecalciferol, calcifediol, alfacalcidol, elocalcitol, seocalcitol, paricalcitol, doxercalciferol, calcitriol and the like, which further have a cis C/D configuration. This includes in particular inecalcitol.
  • the concentration of said 14-epi-analogue in said formulation is comprised between 0.001 and 50% (weight).
  • the oral formulations of the invention may be in the form of a dry formulation, a soft gelatin capsule or a solution, as follows:
  • the oral formulation of the invention may be in the form of a dry formulation which comprises:
  • the oral formulation of the invention comprises between 0.1 and 50% (weight) of CMC.
  • CMC dry formulations of 14-epi-analogues of vitamin D with CMC lead to an improved absorption over the corresponding MCT formulations of said 14-epi-analogues. This result is unexpected as vitamin D analogues have always been consistently formulated in a lipid-based medium such as oils.
  • Dry forms include tablets, pills, powders, hard capsules, pastilles, troches, lozenges and the like. They can contain one or more of any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, cellulose derivatives, gelatin, starch, pregelatinized starch, pyrrolidone, polyvinylpyrrolidone, xanthan gum, or tragacanth gum; a diluent such as powdered sugar, calcium salts, mannitol, sorbitol, kaolin, starch or lactose; a disintegrant such as starch, crospovidone, maltodextrins and cellulose derivatives; a lubricant such as magnesium stearate, calcium stearate, stearic acid, or vegetable oil; a glidant such as talc or colloidal silicon dioxide; an antioxidant such as ascorbic acid, sodium ascorbate, citric acid, tocopherols, alpha-
  • Preferred tablets may contain one or more of carboxymethylcellulose, microcrystalline cellulose, lactose, colloidal silicon dioxide, cornstarch, pregelatinized starch, povidone, crospovidone, maltodextrins, magnesium stearate, alpha-tocopheryl acetate or alpha-tocopherol in any combination.
  • the tablets can be coated for improved long-term stability, for protection against gastric degradation or for controlled or programmed release.
  • the coating is generally achieved with a solution of film forming polymers such as polyvinylic alcohol, polyethylene glycol, cellulose derivatives (esters, ethers or aliphatic substitutions) or acrylic derivatives.
  • the coating can also include pharmaceutically acceptable dyes such as iron oxides, and fillers such as titanium dioxide or talc.
  • Preferred coatings for tablets contain one or more of polyvinylic acohol, polyethylene glycol of various molecular weights, titanium dioxide and talc.
  • the oral formulations of the invention may be in the form of a soft gelatin capsule comprising:
  • the concentration (weight) of LCT is comprised between 1% and qsp.
  • Long Chain Triglyceride refer to long chains comprising more than 14 carbon atoms fatty esters of glycerol. Preferably they comprise 15 to 24 carbon atoms.
  • Long Chain Triglyceride may be chosen from vegetable oils such as arachis oil, olive oil, sunflower oil, canola, cottonseed, corn, linseed, palm, rapeseed, sesame, soybean and their main constituents: glycerol fully esterified with stearic acid, oleic acid, linoleic acid, linolenic acid, eicosanoic acid, eicosenoic acid, behenic acid, erucic acid, tetracosanoic acid, palmitic acid, palmitoleic acid, margaric acid or margaroleic acid or pentadecanoic acid, and their derivatives.
  • Preferred LCT are olive, arachis or sunflower oils, and their mixtures.
  • MCT Medium-chain triglycerides
  • caproic acid caproic acid
  • caprylic acid capric acid
  • lauric acid myristic acid or myristoleic acid
  • myristic acid or myristoleic acid and their derivatives MCT are found in vegetable oils such as coconut oil or palm kernel oil.
  • inecalcitol was better absorbed from LCT (arachis oil, sunflower oil, olive oil) than from MCT as apparent from the results illustrated in FIG. 1 .
  • Soft gelatin capsules are made from gelatin blends, optionally blended with plasticizers such as glycerol, glycerin, sorbitol and sorbitol derivatives.
  • Soft gelatin capsules can be filled with various solutions or emulsions of pharmaceutically active ingredient in LCT alone or mixed with other excipients like surfactants such as polyethyleneglycerides, polysorbates, hydrogenated castor oil and the like, emulsifyers such as phospholipids, semi-synthetic mono- or di-glycerides, propylene glycol, esters of propylene glycol, esters of fatty acids, cholesterol derivatives, lecithins, and the like, or antioxydants such as butylhydroxyanisole, butylhydroxytoluene, ascorbic acid, citric acid, tocopherols or alpha-tocopherol, and the like.
  • surfactants such as polyethyleneglycerides, polysorbates, hydrogenated castor oil and the like,
  • the oral formulations of the invention may be in the form of a solution comprising:
  • the concentration (weight) of propylene glycol is comprised between 1% and qsp.
  • inecalcitol was better absorbed from propylene glycol (e.g. to give rise to peak values more than 15-fold higher and to total bioavailability nearly doubled, in monkeys) than from in MCT.
  • the monoester of propylene glycol with caprylic acid CapmulPG8®
  • increased inecalcitol peak plasma concentration only by a factor less than 2 for an increase in bioavailability limited to about 20% as apparent from FIG. 2 .
  • Propylene glycol formulations may additionally comprise water at a concentration of from 0 to 98.009%.
  • Solutions of the invention may be in the form of syrup or elixir. They may contain sweetening agents, preservatives, dyes, colorings, and flavorings.
  • the liquid compositions may also include binders, buffers, preservatives, chelating agents, sweetening, flavoring and coloring agents, and the like.
  • Formulations include a flavored base, such as sucrose or acacia, and other excipients such as glycocholate.
  • Qsp is used herein to indicate that the ingredient is present in the oral formulation in an amount necessary and/or sufficient to achieve the desired final weight of said formulation. It is thus used to refer to the complementary part or balance quantity of said ingredient.
  • the oral formulations of the invention may be in the form of a unit dose.
  • Such unit doses generally comprise from 0.5 to 20 mg of said 14-epi-analogue.
  • the oral formulations are suitable for use in the prevention and/or treatment of rickets, osteoporosis, osteomalacia, psoriasis, autoimmune diseases such as multiple sclerosis or type I diabetes, hyperparathyroidism, benign prostate hyperplasia, any type of cancer or any vitamin D associated disease.
  • the present invention concerns a method for treating and/or preventing rickets, osteoporosis, osteomalacia, psoriasis, autoimmune diseases such as multiple sclerosis or type I diabetes, hyperparathyroidism, benign prostate hyperplasia, any type of cancer or any vitamin D associated disease, in particular cancer, comprising administering a formulation of the invention to a human or animal patient in need thereof.
  • the formulations of the invention may provide any therapeutically effective amount of said 14-epi-analogue.
  • the administration dose of said 14-epi-analogue is preferably comprised between 1.5 mg and 20 mg.
  • the method of the invention advantageously does not induce increased calcemia in the treated patient.
  • the method of the invention may comprise the administration of said doses of the 14-epi-analogue, at a frequency comprised between every three days up to three times a day, such as every three days, every other day (qod), once-a-day (qd), twice-a-day (bid) or three times a day (tid).
  • the administration may take place every other day, once a day or twice-a-day.
  • a “therapeutically effective amount” refers to an amount of a 14-epi-analogue which is effective in preventing, reducing, eliminating, treating or controlling the symptoms of the herein-described diseases and conditions.
  • the term “controlling” is intended to refer to all processes wherein there may be a slowing, interrupting, arresting, or stopping of the progression of the diseases and conditions described herein, but does not necessarily indicate a total elimination of all disease and condition symptoms, and is intended to include prophylactic treatment.
  • the identification of those subjects who are in need of treatment of herein-described diseases and conditions is well within the ability and knowledge of one skilled in the art. A veterinarian or a physician skilled in the art can readily identify, by the use of clinical tests, physical examination, medical/family history or biological and diagnostic tests, those subjects who are in need of such treatment.
  • a therapeutically effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of conventional techniques and by observing results obtained under analogous circumstances.
  • determining the therapeutically effective amount a number of factors are considered by the attending diagnostician, including, but not limited to: the species of subject; its size, age, and general health; the specific disease involved; the degree of involvement or the severity of the disease; the response of the individual subject; the particular compound administered; the mode of administration; the bioavailability characteristic of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.
  • the amount of a 14-epi-analogue, which is required to achieve the desired biological effect, will vary depending upon a number of factors, including the chemical characteristics (e.g. hydrophobicity) of the compounds employed, the potency of the compounds, the type of disease, the species to which the patient belongs, the diseased state of the patient, the route of administration, the bioavailability of the compound by the chosen route, all factors which dictate the required dose amounts, delivery and regimen to be administered.
  • chemical characteristics e.g. hydrophobicity
  • treating means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
  • the terms “patient” or “patient in need thereof” are intended for an animal or a human being affected or likely to be affected with a pathological condition as discussed above.
  • the patient is human.
  • “pharmaceutically acceptable excipient” includes any carriers, diluents, adjuvants or vehicles, such as preserving or antioxidant agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
  • preserving or antioxidant agents such as preserving or antioxidant agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
  • the use of such media and agents for pharmaceutical active substances is well-known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions as suitable therapeutic combinations.
  • the formulations of the invention may be prepared by admixture of their ingredients.
  • the formulations may conveniently be administered in unit dosage form and may be prepared by any of the methods well-known in the pharmaceutical art, for example, as described in Remington: The Science and Practice of Pharmacy, 20 th ed.; Gennaro, A. R., Ed.; Lippincott Williams & Wilkins: Philadelphia, Pa., 2000.
  • FIG. 1 shows the time-dependent concentration of inecalcitol following its oral administration in LCT (olive oil, sunflower oil and arachis oil) or in MCT in monkeys.
  • LCT live oil, sunflower oil and arachis oil
  • FIG. 2 shows the time-dependent concentration of inecalcitol following its oral administration with capmul, oleic acid or MCT in monkeys, for comparative purposes.
  • FIG. 3 shows the time-dependent concentration of inecalcitol following its oral administration with propylene glycol in monkeys.
  • FIG. 4 shows the time-dependent concentration of inecalcitol following its oral administration with CMC in monkeys.
  • Inecalcitol was dissolved in arachis oil, olive oil, sunflower oil (0.4 mg/ml, i.e. 0.044% w/w), propylene glycol (0.4 mg/ml, i.e. 0.039% w/w), oleic acid (0.4 mg/ml, i.e. 0.045% w/w), MCT (0.4 mg/ml, i.e. 0.042% w/w), or Capmul PG8® (0.4 mg/ml, i.e.
  • Plasma aliquots were prepared on heparinized tubes and unchanged inecalcitol was specifically assayed by HPLC/MS/MS method.
  • Mean pharmacokinetic profiles are plotted in FIGS. 1 to 4 ; the mean maximum concentrations (Cmax) and area under the curve over 24 hours after administration (AUC 0-24h ) were expressed in relation to the mean value observed with the reference solution of inecalcitol in MCT (Table 1); the median time (Tmax) at which Cmax was observed in the different animals receiving the same treatment was determined (Table 1).
  • Composition Unit composition Component centesimal (%) (mg) Inecalcitol 1.333 2.000 Lactose monohydrate 66.967 100.451 Cellulose microcristalline ph 102 11.000 16.500 Carboxymethyl cellulose sodique 3.333 5.000 Crospovidone 15.000 22.500 Anhydrous collidal silicon dioxide 0.500 0.750 Dry vitamin E 50% 1.667 2.501 Magnesium stearate 0.200 0.300 Total raw tablet 100.000 150.002 Opadry II white 85F18422 3.000 Total coated tablet 153.002

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides new formulations of 14-epi-analogues of vitamin D, such as inecalcitol, providing improved absorption profile.

Description

  • The present invention concerns improved formulations of 14-epi-analogues of vitamin D.
  • Vitamin D belongs to the group of fat-soluble vitamins, together with vitamins A, E and K. The two main natural forms of vitamin D: vitamin D2 (also named ergocalciferol) and vitamine D3 (also named cholecalciferol) are soluble in lipids and insoluble in water, like all their chemical derivatives.
  • Vitamin D, its metabolites and analogues have potent effects on calcium and phosphate metabolism and can therefore be used for prevention and therapy of vitamin D deficiency, such as rickets and other disorders of plasma and bone mineral homeostasis such as osteoporosis and osteomalacia. Moreover, vitamin D receptors and vitamin D activity have also been documented in numerous other tissues and cells, where they are also known to be involved in cell proliferation and differentiation. Vitamin D also affects the immune system as vitamin D receptors are expressed in several white blood cells including monocytes, macrophages and T and B lymphocytes.
  • Pharmaceutical formulations of vitamin D compounds as active pharmaceutical ingredients show a large variety: ergocalciferol is available in solution in ethanol for oral administration or in arachis oil for injection since 1940; cholecalciferol is marketed as a solution in medium-chain triglycerides (MCT) both for oral and injectable administrations since 1964; in 1974, a droplet formulation of calcifediol (25-hydroxy-cholecalciferol) in solution in propylene glycol was introduced; in 1979, alfacalcidol (1-hydroxy-cholecalciferol) was approved for oral administration as soft gelatin capsules filled with solution in sesame oil; in 1982, calcitriol (1,25-dihydroxy-cholecalciferol) was launched in soft gelatin capsules filled with solution in MCT; in 1989, a new formulation of cholecalciferol was made available as drinking solution in a complex mixture of polyoxyethylenated glycerides, propylene glycol, glycerol, Cremophor EL and phosphate buffer; in the same year, a new formulation of ergocalciferol was also marketed in a complex mixture of polyoxyethyletaned and glycosylated glycerides; in 2000, a new simple solution of cholecalciferol in olive oil was introduced as a drinking solution; the two latest innovative vitamin D compounds to have been approved for oral pharmaceutical use, doxercalciferol in 1999 and paricalcitol in 2005, are both formulated as solution in MCT in soft gelatin capsules; finally, elocalcitol has recently been developed up to phase IIb clinical trials in soft gelatin capsules containing MCT (U.S. Pat. No. 7,332,482).
  • The absorption of cholecalciferol has been compared when given to human volunteers in solution in identical soft gelatin capsules containing either arachis oil or MCT (Miglyol 812®): in the fasting state, bioavailability of cholecalciferol was about twice higher from arachis oil capsules than from MCT capsules (Holumberg et al., 1990, Biopharm. Drug Disp., 11, 807-8015). When given with a standard meal, no difference was observed.
  • The bioavailability of seocalcitol, a cholecalciferol derivative, was studied in rats in solution either in propylene glycol as the reference formulation, or in two types of lipids: MCT or long chain triglycerides (LCT) (Grove et al., 2005, J. Pharm. Sci., 8, 1830-1838). A two-fold increase in bioavailability of seocalcitol was demonstrated in both lipid formulations over the reference solution in propylene-glycol; no difference was observed between the LCT- or MCT-based formulations.
  • The optimization of the oral delivery of lipophilic compounds in lipid-based formulations has been reviewed (Porter et al., Nature Rev. Drug Discovery, 2007, 6, 231-248). Differences between MCT and LCT on different mechanisms involved in the efficiency of lipophilic drug bioavailability were listed such as drug solubilisation, reduction in gastro-intestinal motility, lymphatic versus hepatic portal transport, secretion of biliary salts and of endogenous phospholipids, or the dynamics of lamellar versus cubic liquid crystal phases in the course of lipid droplet digestion into vesicles, mixed micelles and simple micelles.
  • The complexity of lipid drug absorption has sometimes led to complex formulations incorporating several components playing several different roles such as solvent, surfactant, co-solvent, co-surfactant and the like. Such a complex system has been tested with seocalcitol without any improvement in bioavailability as compared with simple solutions in MCT or LCT (Grove et al., 2006, Eur. J. Pharma. Sci., 28, 233-242).
  • In summary, “the choice of specific formulation components to provide optimal pharmaceutical and biopharmaceutical properties is drug specific and will depend on drug dose and the physicochemical properties of the compound concerned” (Porter et al., ibid, 2007, page 239, box 3). This explains the variety of oral formulations for the variety of vitamin D compounds, although soft gelatin capsules appear to be the most popular galenic form and MCT the most frequent excipient.
  • On the other hand, these so-called non-calcemic effects of vitamin D lead to consider the possible use of vitamin D derivatives for various therapeutic applications such as disorders of the immune system, hormone secretion, cell differentiation or cell proliferation. In particular, such compounds may be useful in the therapy of disorders characterized by increased cell proliferation, such as psoriasis and/or cancer. In particular, 1,25(OH)2-vitamin D3, the active metabolite of vitamin D3 named calcitriol, is known to inhibit the proliferation of many cancer cells lines of various origins in vitro and to slow the progression of various tumor xenografts in vivo.
  • A large number of analogues of calcitriol displaying a clear dissociation between anti-proliferative and calcemic effects have been reported. In particular, EP 0 707 566 B1 discloses a number of calcitriol analogues such as 14-epi-analogues. Among these 14-epi-analogues of calcitriol is inecalcitol of formula:
  • Figure US20120015913A1-20120119-C00001
  • Inecalcitol is the international non-proprietary name for 19-nor-9,10-seco-146H-cholesta-5(Z),7(E)-dien-23-ino-1α,3β,25-triol-23-yne (C26H40O3).
  • Inecalcitol is a synthetic derivative of calcitriol, the natural active metabolite of vitamin D3. Eelen et al. (Molecular Pharmacology 67, 1566-1573, 2005) and Verlinden et al. (Journal of Bone and Mineral Research, volume 16(4), 625-638, 2001) showed the enhanced antiproliferative and markedly lower calcemic effects of inecalcitol compared with calcitriol.
  • Inecalcitol is an original vitamin D analogue different from all other vitamin D derivatives by the cis conformation of the junction between the C and D rings of the molecule, rather than the trans configuration in the natural vitamin D compounds (Verlinden et al., 2000, Cancer Res., 60. 2673-2679). This modification, also called 14-epimerization, has been described for the first time by Maynard et al. (1994, J. Med. Chem., 37, 2387-2393) in the vitamin D series, and only very seldom applied to synthesize new 14-epi-vitamin D analogues (W0 2004 080922 and related patent documents; U.S. Pat. No. 5,936,105; W0 95/01960 and related patent documents; Sawada et al., 2009, Bioorg. Med. Chem., 19, 5397-5400; Sawada et al., 2009, Chem. Pharm. Bull, 57, 1431-1433; Kittaka et al., 2009, Anticancer Res., 9, 3563-3569. Sawada et al.; 2010, J. Steroid Biochem. Mol Biol., doi:10.1016/j.jsbmb.2010.02.035). Inecalcitol is the most advanced 14-epi vitamin D derivative in terms of clinical development: it has been tested both in healthy volunteers and in human patients by oral administration in the classical formulation as a solution in MCT in soft gelatin capsules, like elocalcitol, paricalcitol, doxercalciferol, calcitriol and the first formulation of cholecalciferol.
  • A major feature of inecalcitol profile is its very low calcemic activity, especially in monkeys and human subjects, allowing the oral administration of very high doses. In humans, the maximal tolerated (MDT) dose is 4 mg per day, much higher than the MTD of any other vitamin D analogue previously determined: 10 μg per day for seocalcitol, 45 μg once a week for calcitriol and 150 μg per day for elocalcitol.
  • Thus, inecalcitol, as a representative of a unique physico-chemical class of 14-epi-derivatives of vitamin D, also differs for the range of dose at which it can be administrated. Both reasons may explain the unpredictable results obtained with high dose formulations of inecalcitol orally administrated to monkeys as test animals, more representative of human tolerance than rats.
  • In view of the unique structure and doses, the usual formulations of vitamin D derivatives may not be optimized for the 14-epi-analogues. It is thus desirable to provide improved formulations of 14-epi-analogues of vitamin D, in particular inecalcitol.
  • It is an object of the present invention to provide new oral formulations of 14-epi-analogues of vitamin D, such as inecalcitol, showing an improved absorption profile over the Medium Chain Triglycerides (MCT) formulation of said 14-epi-analogues of vitamin D, in particular in terms of the peak concentration (Cmax).
  • Preferably, the formulations of the invention exhibit at least two-fold increase of the Cmax peak of the MCT formulation in mammals, such as in human and/or monkeys.
  • The formulations of the invention may also exhibit additionally or alternatively an improved overall bioavailability (AUC0-24h) over the Medium Chain Triglycerides formulation of said 14-epi-analogues of vitamin D. Preferably, the formulations of the invention lead to a higher AUC0-24h than the Medium Chain Triglycerides formulation of said 14-epi-analogues of vitamin D in mammals, such as in human and/or monkeys.
  • According to a first object, the present invention concerns an oral formulation of a 14-epi-analogue of vitamin D characterized by an improved absorption profile over the Medium Chain Triglycerides (MCT) formulation of said 14-epi-analogues of vitamin D.
  • According to a second object, the present invention also concerns an oral formulation of a 14-epi-analogue of vitamin D for use for improving the absorption of said 14-epi-analogue over the formulation in medium chain triglycerides.
  • The improved absorption profile is such that the oral formulations of the invention have a higher peak concentration (Cmax) and may additionally exhibit a higher overall absorption (AUC0-24h) than the corresponding formulation in MCT of said 14-epi-analogue of vitamin D.
  • As used herein, the terms “14-epi-analogue of vitamin D” refers to analogues of vitamin D derivatives, such as ergocalciferol, cholecalciferol, calcifediol, alfacalcidol, elocalcitol, seocalcitol, paricalcitol, doxercalciferol, calcitriol and the like, which further have a cis C/D configuration. This includes in particular inecalcitol.
  • In the oral formulations of the invention, the concentration of said 14-epi-analogue in said formulation is comprised between 0.001 and 50% (weight).
  • The oral formulations of the invention may be in the form of a dry formulation, a soft gelatin capsule or a solution, as follows:
  • According to a first embodiment, the oral formulation of the invention may be in the form of a dry formulation which comprises:
      • at least one 14-epi-analogue of vitamin D,
      • carboxymethylcellulose (CMC),
  • and one or more optional pharmaceutically acceptable excipient(s).
  • Generally, the oral formulation of the invention comprises between 0.1 and 50% (weight) of CMC. In particular, it has been surprisingly discovered that dry formulations of 14-epi-analogues of vitamin D with CMC lead to an improved absorption over the corresponding MCT formulations of said 14-epi-analogues. This result is unexpected as vitamin D analogues have always been consistently formulated in a lipid-based medium such as oils.
  • Specifically, it was shown that when inecalcitol was administered to monkeys in suspension in a water solution of the hydrophilic linking/disintegrating excipient CMC, the absorption was better than from any solution of inecalcitol in any lipid-based excipient. Peak concentration was almost 12-fold higher with suspensions in CMC solutions than with solution in MCT. The overall bioavailability was increased by 66% as illustrated in FIG. 4.
  • Dry forms include tablets, pills, powders, hard capsules, pastilles, troches, lozenges and the like. They can contain one or more of any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, cellulose derivatives, gelatin, starch, pregelatinized starch, pyrrolidone, polyvinylpyrrolidone, xanthan gum, or tragacanth gum; a diluent such as powdered sugar, calcium salts, mannitol, sorbitol, kaolin, starch or lactose; a disintegrant such as starch, crospovidone, maltodextrins and cellulose derivatives; a lubricant such as magnesium stearate, calcium stearate, stearic acid, or vegetable oil; a glidant such as talc or colloidal silicon dioxide; an antioxidant such as ascorbic acid, sodium ascorbate, citric acid, tocopherols, alpha-tocopherol or alpha-tocopheryl acetate; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, or glycocholate methyl salicylate.
  • Preferred tablets may contain one or more of carboxymethylcellulose, microcrystalline cellulose, lactose, colloidal silicon dioxide, cornstarch, pregelatinized starch, povidone, crospovidone, maltodextrins, magnesium stearate, alpha-tocopheryl acetate or alpha-tocopherol in any combination.
  • Additionally, the tablets can be coated for improved long-term stability, for protection against gastric degradation or for controlled or programmed release. The coating is generally achieved with a solution of film forming polymers such as polyvinylic alcohol, polyethylene glycol, cellulose derivatives (esters, ethers or aliphatic substitutions) or acrylic derivatives. The coating can also include pharmaceutically acceptable dyes such as iron oxides, and fillers such as titanium dioxide or talc. Preferred coatings for tablets contain one or more of polyvinylic acohol, polyethylene glycol of various molecular weights, titanium dioxide and talc.
  • According to a second aspect, the oral formulations of the invention may be in the form of a soft gelatin capsule comprising:
      • at least one 14-epi-analogue of vitamin D,
      • at least one Long Chain Triglyceride (LCT),
  • and one or more optional pharmaceutically acceptable excipient(s).
  • Generally, in the oral formulation, the concentration (weight) of LCT is comprised between 1% and qsp.
  • It has also been surprisingly discovered that formulations of 14-epi-analogues with Long Chain Triglycerides (LCT) lead to an improved absorption over the corresponding MCT formulations of said 14-epi-analogues. This result is unexpected as this improved activity is not obtained with non esterified corresponding long-chain fatty acid like oleic acid.
  • The terms “Long Chain Triglyceride” refer to long chains comprising more than 14 carbon atoms fatty esters of glycerol. Preferably they comprise 15 to 24 carbon atoms. Long Chain Triglyceride may be chosen from vegetable oils such as arachis oil, olive oil, sunflower oil, canola, cottonseed, corn, linseed, palm, rapeseed, sesame, soybean and their main constituents: glycerol fully esterified with stearic acid, oleic acid, linoleic acid, linolenic acid, eicosanoic acid, eicosenoic acid, behenic acid, erucic acid, tetracosanoic acid, palmitic acid, palmitoleic acid, margaric acid or margaroleic acid or pentadecanoic acid, and their derivatives. Preferred LCT are olive, arachis or sunflower oils, and their mixtures.
  • By contrast, MCT refers to Medium-chain triglycerides (MCTs), comprising 6 to 14 carbons fatty acid esters of glycerol: caproic acid, caprylic acid, capric acid, lauric acid, myristic acid or myristoleic acid, and their derivatives MCT are found in vegetable oils such as coconut oil or palm kernel oil.
  • Specifically, inecalcitol was better absorbed from LCT (arachis oil, sunflower oil, olive oil) than from MCT as apparent from the results illustrated in FIG. 1.
  • Long-chain fatty acid like oleic acid, the majority fatty acid esterified in the olive oil triglycerides, changed the course of inecalcitol absorption by delaying and slightly increasing its peak concentration, but reduced its overall bioavailability, as illustrated in FIG. 2.
  • Soft gelatin capsules are made from gelatin blends, optionally blended with plasticizers such as glycerol, glycerin, sorbitol and sorbitol derivatives. Soft gelatin capsules can be filled with various solutions or emulsions of pharmaceutically active ingredient in LCT alone or mixed with other excipients like surfactants such as polyethyleneglycerides, polysorbates, hydrogenated castor oil and the like, emulsifyers such as phospholipids, semi-synthetic mono- or di-glycerides, propylene glycol, esters of propylene glycol, esters of fatty acids, cholesterol derivatives, lecithins, and the like, or antioxydants such as butylhydroxyanisole, butylhydroxytoluene, ascorbic acid, citric acid, tocopherols or alpha-tocopherol, and the like.
  • According to a third aspect, the oral formulations of the invention may be in the form of a solution comprising:
      • at least one 14-epi-analogue of vitamin D,
      • propylene glycol,
  • and one or more optional pharmaceutically acceptable excipient(s).
  • Generally, in the oral formulations of the invention, the concentration (weight) of propylene glycol is comprised between 1% and qsp.
  • It has further been surprisingly discovered that solutions of 14-epi-analogues of vitamin D in propylene glycol also lead to an improved absorption over the corresponding MCT formulations of said 14-epi-analogues. This result is unexpected as this improved activity is not obtained with the monoester of propylene glycol with caprylic acid (CapmulPG8®).
  • Specifically, inecalcitol was better absorbed from propylene glycol (e.g. to give rise to peak values more than 15-fold higher and to total bioavailability nearly doubled, in monkeys) than from in MCT. These results are illustrated in FIG. 3. However, the monoester of propylene glycol with caprylic acid (CapmulPG8®) increased inecalcitol peak plasma concentration only by a factor less than 2, for an increase in bioavailability limited to about 20% as apparent from FIG. 2.
  • Propylene glycol formulations may additionally comprise water at a concentration of from 0 to 98.009%.
  • Solutions of the invention may be in the form of syrup or elixir. They may contain sweetening agents, preservatives, dyes, colorings, and flavorings.
  • The liquid compositions may also include binders, buffers, preservatives, chelating agents, sweetening, flavoring and coloring agents, and the like.
  • Formulations include a flavored base, such as sucrose or acacia, and other excipients such as glycocholate.
  • “Qsp” is used herein to indicate that the ingredient is present in the oral formulation in an amount necessary and/or sufficient to achieve the desired final weight of said formulation. It is thus used to refer to the complementary part or balance quantity of said ingredient.
  • The oral formulations of the invention may be in the form of a unit dose. Such unit doses generally comprise from 0.5 to 20 mg of said 14-epi-analogue.
  • The oral formulations are suitable for use in the prevention and/or treatment of rickets, osteoporosis, osteomalacia, psoriasis, autoimmune diseases such as multiple sclerosis or type I diabetes, hyperparathyroidism, benign prostate hyperplasia, any type of cancer or any vitamin D associated disease.
  • According to a further object, the present invention concerns a method for treating and/or preventing rickets, osteoporosis, osteomalacia, psoriasis, autoimmune diseases such as multiple sclerosis or type I diabetes, hyperparathyroidism, benign prostate hyperplasia, any type of cancer or any vitamin D associated disease, in particular cancer, comprising administering a formulation of the invention to a human or animal patient in need thereof.
  • The formulations of the invention may provide any therapeutically effective amount of said 14-epi-analogue. The administration dose of said 14-epi-analogue is preferably comprised between 1.5 mg and 20 mg.
  • The method of the invention advantageously does not induce increased calcemia in the treated patient.
  • The method of the invention may comprise the administration of said doses of the 14-epi-analogue, at a frequency comprised between every three days up to three times a day, such as every three days, every other day (qod), once-a-day (qd), twice-a-day (bid) or three times a day (tid). Preferably, the administration may take place every other day, once a day or twice-a-day.
  • As used herein, a “therapeutically effective amount” refers to an amount of a 14-epi-analogue which is effective in preventing, reducing, eliminating, treating or controlling the symptoms of the herein-described diseases and conditions. The term “controlling” is intended to refer to all processes wherein there may be a slowing, interrupting, arresting, or stopping of the progression of the diseases and conditions described herein, but does not necessarily indicate a total elimination of all disease and condition symptoms, and is intended to include prophylactic treatment. The identification of those subjects who are in need of treatment of herein-described diseases and conditions is well within the ability and knowledge of one skilled in the art. A veterinarian or a physician skilled in the art can readily identify, by the use of clinical tests, physical examination, medical/family history or biological and diagnostic tests, those subjects who are in need of such treatment.
  • A therapeutically effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of conventional techniques and by observing results obtained under analogous circumstances. In determining the therapeutically effective amount, a number of factors are considered by the attending diagnostician, including, but not limited to: the species of subject; its size, age, and general health; the specific disease involved; the degree of involvement or the severity of the disease; the response of the individual subject; the particular compound administered; the mode of administration; the bioavailability characteristic of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.
  • The amount of a 14-epi-analogue, which is required to achieve the desired biological effect, will vary depending upon a number of factors, including the chemical characteristics (e.g. hydrophobicity) of the compounds employed, the potency of the compounds, the type of disease, the species to which the patient belongs, the diseased state of the patient, the route of administration, the bioavailability of the compound by the chosen route, all factors which dictate the required dose amounts, delivery and regimen to be administered.
  • In the context of the invention, the term “treating” or “treatment”, as used herein, means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
  • According to the invention, the terms “patient” or “patient in need thereof” are intended for an animal or a human being affected or likely to be affected with a pathological condition as discussed above. Preferably, the patient is human.
  • As used herein, “pharmaceutically acceptable excipient” includes any carriers, diluents, adjuvants or vehicles, such as preserving or antioxidant agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well-known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions as suitable therapeutic combinations.
  • The formulations of the invention may be prepared by admixture of their ingredients.
  • The formulations may conveniently be administered in unit dosage form and may be prepared by any of the methods well-known in the pharmaceutical art, for example, as described in Remington: The Science and Practice of Pharmacy, 20th ed.; Gennaro, A. R., Ed.; Lippincott Williams & Wilkins: Philadelphia, Pa., 2000.
  • FIGURES
  • FIG. 1 shows the time-dependent concentration of inecalcitol following its oral administration in LCT (olive oil, sunflower oil and arachis oil) or in MCT in monkeys.
  • FIG. 2 shows the time-dependent concentration of inecalcitol following its oral administration with capmul, oleic acid or MCT in monkeys, for comparative purposes.
  • FIG. 3 shows the time-dependent concentration of inecalcitol following its oral administration with propylene glycol in monkeys.
  • FIG. 4 shows the time-dependent concentration of inecalcitol following its oral administration with CMC in monkeys.
  • The following examples are given for illustrative and non-limiting purpose.
  • EXAMPLE 1
  • Inecalcitol was dissolved in arachis oil, olive oil, sunflower oil (0.4 mg/ml, i.e. 0.044% w/w), propylene glycol (0.4 mg/ml, i.e. 0.039% w/w), oleic acid (0.4 mg/ml, i.e. 0.045% w/w), MCT (0.4 mg/ml, i.e. 0.042% w/w), or Capmul PG8® (0.4 mg/ml, i.e. 0.044% w/w), or dispersed as a fine milky suspension in pharmaceutical grade distilled water containing 0.5% (w/v) carboxymethylcellulose, corresponding to a 3.33% w/w concentration in the tablet formulation (5 mg CMC and 2 mg Inecalcitol in each tablet weighing 150 mg without coating). Male cynomolgus monkey received a single oral administration of a high dose of inecalcitol (2 mg/kg) in the same volume (5 ml/kg) for each excipient. Blood samples were drawn at the time of administration (To) and 15, 30, 45, 60, 90 minutes, 3, 6, 9 and 24 hours later. Plasma aliquots were prepared on heparinized tubes and unchanged inecalcitol was specifically assayed by HPLC/MS/MS method. Mean pharmacokinetic profiles (±SEM) are plotted in FIGS. 1 to 4; the mean maximum concentrations (Cmax) and area under the curve over 24 hours after administration (AUC0-24h) were expressed in relation to the mean value observed with the reference solution of inecalcitol in MCT (Table 1); the median time (Tmax) at which Cmax was observed in the different animals receiving the same treatment was determined (Table 1).
  • TABLE 1
    Excipient Cmax (−fold) Tmax (h) AUC0-24 h (%) N
    MCT 1 0.25 100 6
    Oleic acid 1.7 3  67% 4
    Capmul PG8 1.9 3 121% 3
    Arachis oil 3.2 1  91% 4
    Sunflower oil 3.0 1.5 132% 4
    Olive oil 4.3 1 127% 4
    CMC-water 11.6 0.5 166% 9
    Propylene 16.5 0.75 193% 3
    glycol
    N: Total number of monkeys per formulation
  • It appears that inecalcitol was better absorbed from LCT (arachis oil, sunflower oil, olive oil) than from MCT (FIG. 1; Table 1). Long-chain fatty acid like oleic acid, the majority fatty acid esterified in the olive oil triglycerides, changed the course of inecalcitol absorption by delaying and slightly increasing its peak concentration (FIG. 2; Table 1).
  • It also appears that solution of inecalcitol in propylene glycol was even more readily absorbed to give rise to peak values more than 15-fold higher than from in MCT. The resulting total bioavailability was nearly doubled (FIG. 3; Table 1). However, the monoester of propylene glycol with caprylic acid (CapmulPG8®) increased inecalcitol peak plasma concentration only by a factor of 2, for an increase in bioavailability limited to about 20% (FIG. 2; Table 1).
  • Even more striking, when inecalcitol was administrated to monkeys in suspension in a water solution of the hydrophilic linking/disintegrating excipient carboxymethylcellulose (CMC), the absorption was better than from any solution of inecalcitol in any lipid-based excipient. Peak concentration was almost 12-fold higher with suspensions in CMC solutions than with solution in MCT. The overall bioavailability was increased by 66% (FIG. 4; Table 1).
  • EXAMPLE 2 Composition of 2 mg Inecalcitol Tablets
  • Composition Unit composition
    Component centesimal (%) (mg)
    Inecalcitol 1.333 2.000
    Lactose monohydrate 66.967 100.451
    Cellulose microcristalline ph 102 11.000 16.500
    Carboxymethyl cellulose sodique 3.333 5.000
    Crospovidone 15.000 22.500
    Anhydrous collidal silicon dioxide 0.500 0.750
    Dry vitamin E 50% 1.667 2.501
    Magnesium stearate 0.200 0.300
    Total raw tablet 100.000 150.002
    Opadry II white 85F18422 3.000
    Total coated tablet 153.002

Claims (14)

1. An oral formulation of a 14-epi-analogue of vitamin D, characterized by an improved absorption profile over the Medium Chain Triglycerides (MCT) formulation of said 14-epi-analogues of vitamin D.
2. An oral formulation of a 14-epi-analogue of vitamin D for use for improving the absorption of said 14-epi-analogue over the formulation in medium chain triglyceride.
3. The oral formulation according to claim 1, wherein it is characterized by a higher peak concentration (Cmax) and optionally a higher overall absorption (AUC0-24h) than the corresponding formulation in MCT.
4. The oral formulation according to claim 1, wherein said formulation is a dry formulation which comprises:
at least one 14-epi-analogue of vitamin D,
carboxymethylcellulose (CMC),
and one or more optional pharmaceutically acceptable excipient(s).
5. The oral formulation according to claim 4, which comprises between 0.1% and 50% (weight) of CMC.
6. The oral formulation according to claim 1, wherein said formulation is a soft gelatin capsule comprising:
at least one 14-epi-analogue of vitamin D,
at least one Long Chain Triglyceride (LCT),
and one or more optional pharmaceutically acceptable excipient(s).
7. The oral formulation according to claim 6, wherein the concentration (weight) of LCT is comprised between 1% and qsp.
8. The oral formulation according to claim 1, wherein said formulation is a solution comprising:
at least one 14-epi-analogue of vitamin D,
propylene glycol,
and one or more optional pharmaceutically acceptable excipient(s).
9. The oral formulation according to claim 8, wherein the concentration (weight) of propylene glycol is comprised between 1% and qsp.
10. The oral formulation according to claim 1, wherein said 14-epi-analogue of vitamin D is inecalcitol.
11. The oral formulation according to claim 1, wherein the concentration of said 14-epi-analogue in said formulation is comprised between 0.001 and 50% (weight).
12. The oral formulation according to claim 1 in a unit dose.
13. The oral formulation according to claim 1, which comprises from 0.5 to 20 mg of said 14-epi-analogue.
14. A method for the prevention and/or treatment of rickets, osteoporosis, osteomalacia, psoriasis, autoimmune diseases such as multiple sclerosis or type I diabetes, hyperparathyroidism, benign prostate hyperplasia, any type of cancer or any vitamin D associated disease comprising administering the oral formulation according to claim 1.
US12/836,974 2010-07-15 2010-07-15 Formulations of 14-EPI-Analogues of Vitamin D Abandoned US20120015913A1 (en)

Priority Applications (42)

Application Number Priority Date Filing Date Title
US12/836,974 US20120015913A1 (en) 2010-07-15 2010-07-15 Formulations of 14-EPI-Analogues of Vitamin D
SI201130021T SI2407155T1 (en) 2010-07-15 2011-07-13 Formulations of inecalcitol
PT111738365T PT2407154E (en) 2010-07-15 2011-07-13 Formulations of 14-epi-analogues of vitamin d
JP2013519097A JP5836373B2 (en) 2010-07-15 2011-07-13 New formulation of 14-epi-analogue of vitamin D
NZ606678A NZ606678A (en) 2010-07-15 2011-07-13 Formulations of 14-epi-analogues of vitamin d
AU2011278352A AU2011278352B2 (en) 2010-07-15 2011-07-13 Formulations of 14 - epi -analogues of vitamin D
UAA201301824A UA110211C2 (en) 2010-07-15 2011-07-13 New storage 14-ei-vitamin d analogues
CA2805198A CA2805198C (en) 2010-07-15 2011-07-13 New formulations of 14-epi-analogues of vitamin d and cmc
KR1020137003059A KR101821440B1 (en) 2010-07-15 2011-07-13 New formulations of 14-epi-analogues of vitamin d
PL11173836T PL2407154T3 (en) 2010-07-15 2011-07-13 Formulations of 14-epi-analogues of vitamin D
KR1020137003060A KR101821441B1 (en) 2010-07-15 2011-07-13 Formulations of 14-epi-analogues of vitamin d
US13/182,239 US9314474B2 (en) 2010-07-15 2011-07-13 Formulations of 14-epi-analogues of vitamin D
SI201130012T SI2407154T1 (en) 2010-07-15 2011-07-13 Formulations of 14-epi-analogues of vitamin D
CN201180043277.7A CN103096877B (en) 2010-07-15 2011-07-13 The new formulation of 14 epimerism analogs of vitamin D
EP11173860A EP2407155B1 (en) 2010-07-15 2011-07-13 Formulations of inecalcitol
PCT/EP2011/061973 WO2012007512A1 (en) 2010-07-15 2011-07-13 New formulations of 14 - epi -analogues of vitamin d
US13/182,251 US20120015915A1 (en) 2010-07-15 2011-07-13 Formulations of 14-epi-analogues of vitamin d
RU2013106492/15A RU2575819C2 (en) 2010-07-15 2011-07-13 New formulations of 14-epi-analogues of vitamin d
PCT/EP2011/061984 WO2012007517A1 (en) 2010-07-15 2011-07-13 Formulations of 14 - epi -analogues of vitamin d
EP11173836A EP2407154B1 (en) 2010-07-15 2011-07-13 Formulations of 14-epi-analogues of vitamin D
RU2013106493/15A RU2575792C2 (en) 2010-07-15 2011-07-13 Formulations of vitamin d 14-epi-analogues
SG2013002902A SG187071A1 (en) 2010-07-15 2011-07-13 New formulations of 14 - epi -analogues of vitamin d
SG2013002910A SG187072A1 (en) 2010-07-15 2011-07-13 Formulations of 14 - epi -analogues of vitamin d
JP2013519093A JP5836372B2 (en) 2010-07-15 2011-07-13 New formulation of 14-epi-analogue of vitamin D
BR112013000930A BR112013000930A2 (en) 2010-07-15 2011-07-13 14-epi analog formulations of vitamin d and cmc
MX2013000539A MX2013000539A (en) 2010-07-15 2011-07-13 New formulations of 14 - epi -analogues of vitamin d.
DK11173836.5T DK2407154T3 (en) 2010-07-15 2011-07-13 Formulations of 14-epi analogues of vitamin D
CN2011800432762A CN103096876A (en) 2010-07-15 2011-07-13 New formulations of 14-epi-analogues of vitamin D
AU2011278346A AU2011278346B2 (en) 2010-07-15 2011-07-13 New formulations of 14 - epi -analogues of vitamin D
ES11173860T ES2401715T3 (en) 2010-07-15 2011-07-13 Inecalcitol formulations
ES11173836T ES2398640T3 (en) 2010-07-15 2011-07-13 Formulations of 14-epi analogs of vitamin D
DK11173860.5T DK2407155T3 (en) 2010-07-15 2011-07-13 Formulations of inecalcitol
PL11173860T PL2407155T3 (en) 2010-07-15 2011-07-13 Formulations of inecalcitol
BR112013000941A BR112013000941A2 (en) 2010-07-15 2011-07-13 14-epi-analog formulations of vitamin d
NZ606679A NZ606679A (en) 2010-07-15 2011-07-13 Formulations of 14-epi-analogues of vitamin d and cmc
CA2805203A CA2805203A1 (en) 2010-07-15 2011-07-13 Formulations of 14 - epi -analogues of vitamin d
PT111738605T PT2407155E (en) 2010-07-15 2011-07-13 Formulations of inecalcitol
PCT/EP2011/062127 WO2012007570A2 (en) 2010-07-15 2011-07-15 New formulations of 14-epi-analogues of vitamin d
IL224191A IL224191A (en) 2010-07-15 2013-01-13 Formulations of 14 -epi-analogues of vitamin d and cmc
IL224192A IL224192A (en) 2010-07-15 2013-01-13 Formulations of 14- epi-analogues of vitamin d
HRP20130093AT HRP20130093T1 (en) 2010-07-15 2013-02-04 Formulations of 14-epi-analogues of vitamin d
HRP20130237AT HRP20130237T1 (en) 2010-07-15 2013-03-19 Formulations od inecalcitol

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/836,974 US20120015913A1 (en) 2010-07-15 2010-07-15 Formulations of 14-EPI-Analogues of Vitamin D

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/182,239 Continuation US9314474B2 (en) 2010-07-15 2011-07-13 Formulations of 14-epi-analogues of vitamin D
US13/182,251 Continuation US20120015915A1 (en) 2010-07-15 2011-07-13 Formulations of 14-epi-analogues of vitamin d

Publications (1)

Publication Number Publication Date
US20120015913A1 true US20120015913A1 (en) 2012-01-19

Family

ID=45467429

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/836,974 Abandoned US20120015913A1 (en) 2010-07-15 2010-07-15 Formulations of 14-EPI-Analogues of Vitamin D
US13/182,239 Expired - Fee Related US9314474B2 (en) 2010-07-15 2011-07-13 Formulations of 14-epi-analogues of vitamin D
US13/182,251 Abandoned US20120015915A1 (en) 2010-07-15 2011-07-13 Formulations of 14-epi-analogues of vitamin d

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/182,239 Expired - Fee Related US9314474B2 (en) 2010-07-15 2011-07-13 Formulations of 14-epi-analogues of vitamin D
US13/182,251 Abandoned US20120015915A1 (en) 2010-07-15 2011-07-13 Formulations of 14-epi-analogues of vitamin d

Country Status (2)

Country Link
US (3) US20120015913A1 (en)
UA (1) UA110211C2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160283412A1 (en) * 2015-03-23 2016-09-29 International Business Machines Corporation Communication mode control for wearable devices

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150246061A1 (en) * 2012-10-19 2015-09-03 Celus Pharmaceuticals, Inc. Vitamin d analogues for the treatment of a neurological disorder
CN104751064A (en) * 2013-12-27 2015-07-01 珠海金山办公软件有限公司 Document encryption prompting method and document encryption prompting system

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672358A (en) * 1994-06-21 1997-09-30 Ascent Pharmaceuticals, Inc. Controlled release aqueous emulsion
US20020006443A1 (en) * 1999-12-23 2002-01-17 Curatolo William J. Pharmaceutical compositions providing enhanced drug concentrations
US20060189576A1 (en) * 2003-03-10 2006-08-24 Roger Bouillon Substituted vitamin d analogues and their therapeutic uses
US8481514B2 (en) * 2009-05-20 2013-07-09 Hybrigenics Sa Therapeutical uses of inecalcitol

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0707566T3 (en) 1993-07-09 2000-09-04 Theramex Hitherto unknown structural analogues for vitamin D
ITFI970184A1 (en) 1997-07-30 1999-01-30 Menarini Farma Ind PHARMACEUTICAL COMPOSITIONS CONTAINING VITAMIN D AND CALCIUM, THEIR PREPARATION AND THERAPEUTIC USE
AUPP022297A0 (en) * 1997-11-06 1997-11-27 R.P. Scherer Holdings Pty Ltd Vitamin coating
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
FR2801307B1 (en) * 1999-11-24 2002-12-06 Galderma Res & Dev VITAMIN D ANALOGS
US20050020546A1 (en) 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
GB0423091D0 (en) 2004-10-19 2004-11-17 Leuven K U Res & Dev Bioactive vitamin d analogues
US20070093458A1 (en) 2005-07-18 2007-04-26 Anchel Schwartz Preparation of paricalcitol and crystalline forms thereof
US20080145411A1 (en) 2006-10-06 2008-06-19 Kaneka Corporation Composition of high absorbability for oral administration comprising oxidized coenzyme q10
BRPI0811102A2 (en) 2007-05-15 2014-09-23 Puretech Ventures METHODS AND COMPOSITIONS FOR TREATING SKIN CONDITIONS
EP2200613B1 (en) * 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
JP2010111593A (en) 2008-11-04 2010-05-20 Teijin Pharma Ltd 14-epi-19-norprevitamin d3 derivative
EP2407154B1 (en) 2010-07-15 2012-11-07 Hybrigenics Formulations of 14-epi-analogues of vitamin D

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672358A (en) * 1994-06-21 1997-09-30 Ascent Pharmaceuticals, Inc. Controlled release aqueous emulsion
US20020006443A1 (en) * 1999-12-23 2002-01-17 Curatolo William J. Pharmaceutical compositions providing enhanced drug concentrations
US20060189576A1 (en) * 2003-03-10 2006-08-24 Roger Bouillon Substituted vitamin d analogues and their therapeutic uses
US8481514B2 (en) * 2009-05-20 2013-07-09 Hybrigenics Sa Therapeutical uses of inecalcitol

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160283412A1 (en) * 2015-03-23 2016-09-29 International Business Machines Corporation Communication mode control for wearable devices

Also Published As

Publication number Publication date
UA110211C2 (en) 2015-12-10
US20120015915A1 (en) 2012-01-19
US20120015914A1 (en) 2012-01-19
US9314474B2 (en) 2016-04-19

Similar Documents

Publication Publication Date Title
US8722664B2 (en) Spontaneously dispersible N-benzoyl staurosporine compositions
UA120508C2 (en) Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US20220071983A1 (en) Pharmaceutical Composition
AU2011278352B2 (en) Formulations of 14 - epi -analogues of vitamin D
US9314474B2 (en) Formulations of 14-epi-analogues of vitamin D
EP2407152A1 (en) Formulations of 14-epi-analogues of vitamin D
RU2575819C2 (en) New formulations of 14-epi-analogues of vitamin d
RU2575792C2 (en) Formulations of vitamin d 14-epi-analogues
US20240325416A1 (en) Oral solid dosage forms comprising cannabinoids
CA2618084A1 (en) Microparticle compositions of the topoisomerase i inhibitor 7-tert-butoxyiminomethylcamptothecin

Legal Events

Date Code Title Description
AS Assignment

Owner name: HYBRIGENICS SA, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DELANSORNE, REMI;REEL/FRAME:025220/0858

Effective date: 20100924

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION